X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
GMRx2 is a single-pill, multi-mechanism, triple combination of telmisartan, amlodipine and indapamide, in novel and proprietary dosage strengths and is in Phase III development for hypertension and for the prevention of recurrent intracerebral haemorrhage.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 12, 2023
Details:
GMRx2 is George Medicine’s most advanced candidate in late-stage development. A single-pill triple combination, it contains low doses of the commonly used hypertension medications telmisartan, amlodipine and indapamide.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
GMRx2 is a single pill triple combination in novel and proprietary dosage strengths containing telmisartan, amlodipine and indapamide, targeted for first line therapy to control hypertension.
Lead Product(s): Telmisartan,Amlodipine,Indapamide
Therapeutic Area: Cardiology/Vascular Diseases Product Name: GMRx2
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
